Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Positive pivotal phase III data for Epolong in CKD

Dec. 11, 2020

Galapagos begins phase II trial of CFTR inhibitor GLPG-2737 for ADPKD

Dec. 3, 2020

Allena presents initial phase I data on ALLN-346 for hyperuricemia

Dec. 1, 2020

Experimental aorta transplantation ameliorates uremic vascular calcification in rats

Nov. 12, 2020

EZH2 as novel therapeutic target for chronic kidney disease

Nov. 12, 2020

Janssen Pharmaceutica discloses BARK1 inhibitors

Nov. 11, 2020

Phase III CARDINAL study of bardoxolone in Alport syndrome meets primary endpoint

Nov. 10, 2020

Phase III trial of Nefecon in primary IgAN meets key endpoints

Nov. 9, 2020

CaMK4 as potential target to slow cyst growth in PKD

Nov. 9, 2020

SYNB-8802 consumes GI oxalate in animals with acute hyperoxaluria

Nov. 6, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...